Keyphrases
Colombia
88%
Frailty Syndrome
57%
Dialysis Facility
57%
Frailty
51%
Age-related Illnesses
38%
Over 65
34%
Older People
34%
Older Adults
34%
Chronic Kidney Disease
34%
End-stage Kidney Disease
33%
Fried Criteria
28%
Adult Cancer
28%
Edmonton Frail Scale
28%
Pure Red Cell Aplasia
28%
Immune Checkpoint Inhibitors
28%
Dementia Prevalence
28%
Geriatric Frailty
28%
Oral Anticoagulation
28%
Non-valvular Atrial Fibrillation
28%
Hypertension
28%
Colombians
28%
Latin America (LATAM)
28%
Type 2 Diabetes Mellitus (T2DM)
28%
Peruvian
28%
Community-acquired Pneumonia
28%
Health Systems
28%
Internal Medicine
28%
Santander
28%
Metastatic Melanoma
28%
Medical Education
28%
Functional Capacity
28%
Aging
28%
Kidney Disease Outcome
28%
Latin American
28%
Functional Limitations
23%
Renal Replacement Therapy
20%
Adverse Outcomes
20%
Pharmacological Adherence
19%
Therapeutic Adherence
19%
Low Adherence
19%
Confidence Interval
17%
Adverse Reactions
16%
Hematologic
16%
Frail Elderly
14%
Cognitive Dysfunction
11%
Older Adult Population
11%
Cox Regression Model
11%
Medical Records
11%
Risk Factors
11%
Activities of Daily Living
11%
Medicine and Dentistry
Prevalence
100%
Frailty
85%
Frailty Syndrome
57%
Hemodialysis
57%
Geriatric Syndrome
38%
Geriatrics
36%
Chronic Kidney Disease
34%
End Stage Renal Disease
33%
Pure Red Cell Aplasia
28%
Metastatic Melanoma
28%
Immune Checkpoint Inhibitor
28%
Type 2 Diabetes
28%
Community-Acquired Pneumonia
28%
Anticoagulation
28%
Internal Medicine
28%
Malignant Neoplasm
28%
Atrial Fibrillation
28%
Maturity Onset Diabetes of the Young
28%
Health System
28%
Systematic Review
28%
Functional Status
28%
Functional Limitation
28%
Renal Replacement Therapy
20%
Adverse Outcome
20%
Antithrombotic
19%
Creatinine
15%
Proportional Hazards Model
14%
Medical Record
14%
Secondary Data
14%
Cognitive Defect
14%
Chronic Disease
13%
Adverse Event
11%
Cross Sectional Study
10%
Drug Therapy
9%
Elderly Population
9%
Observational Study
9%
Antiplatelet Drug
9%
Apoplexy
9%
Polypharmacy
9%
Bivariate Analysis
9%
Anticoagulant Therapy
9%
Arrhythmia
9%
Albumin
9%
Family Assessment
7%
Barthel Index
7%
Vulnerable Population
7%
Prospective Cohort Study
7%
Intervention Study
7%
Hazard Ratio
7%
Multivariate Analysis
7%
Pharmacology, Toxicology and Pharmaceutical Science
Frailty
86%
Prevalence
79%
Syndrome
67%
Hemodialysis
57%
End Stage Renal Disease
32%
Chronic Kidney Failure
32%
Malignant Neoplasm
28%
Community Acquired Pneumonia
28%
Anticoagulant Agent
28%
Atrial Fibrillation
28%
Non Insulin Dependent Diabetes Mellitus
28%
Adverse Outcome
16%
Replacement Therapy
14%
Creatinine
10%
Antithrombocytic Agent
9%
Observational Study
9%
Heart Arrhythmia
9%
Polypharmacy
9%
Cerebrovascular Accident
9%
Cross-Sectional Study
9%
Prospective Cohort Study
7%
Lung Cancer
7%
Intervention Study
7%
Albumin
7%
Limited Mobility
5%
Sarcopenia
5%
